Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch :
Am J Nurs. 2022 Aug 1;122(8):23. doi: 10.1097/01.NAJ.0000854972.82263.fc.
Axicabtagene ciloleucel (Yescarta) has been approved for use as a second-line drug in patients with large B-cell lymphoma who are resistant to, or who relapse within 12 months of, first-line chemoimmunotherapy.Confirming the patient's identity and matching it to the drug are critical as this is an autologous infusion. Nurses should premedicate patients to minimize the risk of hypersensitivity reactions.
阿基仑赛（Yescarta）已被批准用于一线化疗免疫治疗耐药或治疗后 12 个月内复发的大 B 细胞淋巴瘤患者的二线药物。由于这是一种自体输注，确认患者身份并与药物匹配至关重要。护士应预先给患者用药，以最大程度降低过敏反应的风险。
